Skip to content
Open in App
Biogen logo

Biogen

web2

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Eur...

Symbol · BIIB
Company profile

About

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

Biogen completes RayThera acquisition

KEY STEP

Biogen completed its acquisition of RayThera, adding multiple immunology assets. The lead program had entered Phase 1 development in July 2026.

Roadmap reference

LEQEMBI IQLIK initiation therapy becomes available in the United States

KEY STEP

Biogen and Eisai announced that once weekly LEQEMBI IQLIK autoinjector for initiation therapy became available in the United States for adults with early Alzheimer’s disease.

Roadmap reference
People

Company team

MC

Maria C. Freire

Independent Chair of the Board

Company leadership profile.

CA

Christopher A. Viehbacher

President, CEO & Director

Company leadership profile.

JB

Jesus B. Mantas

Independent Director

Company leadership profile.

MD

Monish D. Patolawala

Independent Director

Company leadership profile.

EK

Eric K. Rowinsky

Independent Director

Company leadership profile.

SA

Stephen A. Sherwin

Independent Director

Company leadership profile.

WA

William Allen Hawkins

Independent Director

Company leadership profile.

SK

Susan K. Langer

Independent Director

Company leadership profile.

LB

Lloyd B. Minor

Independent Director

Company leadership profile.

MN

Menelas Nicolas Pangalos

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Biogen.

Orbitrum research

Experts evaluating Biogen

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment